Prostate cancer in renal transplant recipients. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Nephrology Dialysis Transplantation Year : 2008

Prostate cancer in renal transplant recipients.


BACKGROUND: We conducted a retrospective multi-centre study to determine the characteristics of prostate cancer in renal transplant recipients (RTR) and to analyse the relation with immunosuppressive maintenance therapies. METHODS: Patients from 19 French transplant centres diagnosed with prostate cancer at least 1 year after kidney transplantation were included in this study. Data regarding demographics, kidney transplantation, prostate cancer and immunosuppressive treatment were analysed. RESULTS: Sixty-two patients met the eligibility criteria for this study. Thirty-eight patients (61.3%) received calcineurin inhibitors (CNI) and azathioprine (AZA) with or without steroids, twenty received CNI with or without steroids (32.2%) and four received CNI and mycophenolate mofetil (6.5%). Patients with CNI and AZA immunosuppressive therapy presented more high-stage cancer (T3 and T4) when compared to patients receiving CNI alone (47.5% versus 15%, respectively, P = 0.03). A non-significant increase in lymph node invasion was found in patients receiving CNI and AZA compared to patients receiving CNI alone (21% versus 5%, P = 0.16). In the multivariate analysis, the immunosuppressive regimen with CNI and AZA was the only independent risk factor for locally advanced disease (P = 0.007). CONCLUSION: Our results showed that RTR are at risk for early occurrence and for locally advanced prostate cancer, especially when they received a CNI and AZA maintenance immunosuppressive therapy.



Dates and versions

inserm-00484157 , version 1 (18-05-2010)



François M. Kleinclauss, Marc Gigante, Yann Neuzillet, Marc Mouzin, Nicolas Terrier, et al.. Prostate cancer in renal transplant recipients.. Nephrology Dialysis Transplantation, 2008, 23 (7), pp.2374-80. ⟨10.1093/ndt/gfn008⟩. ⟨inserm-00484157⟩
101 View
0 Download



Gmail Facebook Twitter LinkedIn More